MCID: VSC008
MIFTS: 36

Vascular Hemostatic Disease

Categories: Cardiovascular diseases, Blood diseases

Aliases & Classifications for Vascular Hemostatic Disease

MalaCards integrated aliases for Vascular Hemostatic Disease:

Name: Vascular Hemostatic Disease 12 14
Vascular Hemostatic Disorders 69
Hemostatic Disorders 41

Classifications:



External Ids:

Disease Ontology 12 DOID:484
MeSH 41 D020141
SNOMED-CT 64 21112004
UMLS 69 C0600502

Summaries for Vascular Hemostatic Disease

MalaCards based summary : Vascular Hemostatic Disease, also known as vascular hemostatic disorders, is related to thrombophilia due to activated protein c resistance and thrombophilia due to protein c deficiency, autosomal dominant. An important gene associated with Vascular Hemostatic Disease is KRIT1 (KRIT1, Ankyrin Repeat Containing). The drugs Bortezomib and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and t cells, and related phenotype is cardiovascular system.

Related Diseases for Vascular Hemostatic Disease

Diseases related to Vascular Hemostatic Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 41)
# Related Disease Score Top Affiliating Genes
1 thrombophilia due to activated protein c resistance 10.9
2 thrombophilia due to protein c deficiency, autosomal dominant 10.8
3 thrombophilia, x-linked, due to factor ix defect 10.8
4 thrombophilia due to protein c deficiency, autosomal recessive 10.8
5 thrombophilia due to protein s deficiency, autosomal dominant 10.8
6 heparin cofactor ii deficiency 10.8
7 thrombophilia due to histidine-rich glycoprotein deficiency 10.8
8 antithrombin iii deficiency 10.8
9 protein z deficiency 10.8
10 thrombophilia due to thrombomodulin defect 10.8
11 intracranial structure hemangioma 10.2 KRIT1 SNRPB
12 brain angioma 10.2 KRIT1 SNRPB
13 cerebral angioma 10.1 KRIT1 SNRPB
14 hemangioma of intra-abdominal structure 10.1 HBA1 KRIT1
15 hemangioma of liver 10.0 F2 HBA1 KRIT1
16 human venous malformation 9.9 CCM2 KRIT1 PDCD10
17 cavernous malformation 9.9 CCM2 KRIT1 PDCD10
18 cavernous hemangioma 9.8 CCM2 F2 KRIT1
19 klippel-trenaunay-weber syndrome 9.8 CCM2 KRIT1 PDCD10
20 venous malformations, multiple cutaneous and mucosal 9.8 CCM2 KRIT1 PDCD10
21 cerebral cavernous malformations 9.8 CCM2 KRIT1 PDCD10
22 sickle cell anemia 9.8 F2 HBA1
23 central nervous system hemangioma 9.7 CCM2 KRIT1 PDCD10 SNRPB
24 cerebral cavernous malformations 3 9.7 CCM2 KRIT1 PDCD10 SNRPB
25 cerebral cavernous malformations 2 9.7 CCM2 KRIT1 PDCD10 SNRPB
26 cell type benign neoplasm 9.7 CCM2 KRIT1 PDCD10 SNRPB
27 arteries, anomalies of 9.6
28 blood group, i system 9.6
29 rheumatoid arthritis 9.6
30 anemia, autoimmune hemolytic 9.6
31 aging 9.6
32 myocardial infarction 9.6
33 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 9.6
34 graft-versus-host disease 9.6
35 arthritis 9.6
36 hemolytic anemia 9.6
37 thrombocytopenia 9.6
38 peripheral artery disease 9.6
39 myeloproliferative neoplasm 9.6
40 chronic graft versus host disease 9.6
41 pituitary tumors 9.6

Graphical network of the top 20 diseases related to Vascular Hemostatic Disease:



Diseases related to Vascular Hemostatic Disease

Symptoms & Phenotypes for Vascular Hemostatic Disease

MGI Mouse Phenotypes related to Vascular Hemostatic Disease:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.1 CCM2 CD2AP F2 KRIT1 PDCD10 SLC12A2

Drugs & Therapeutics for Vascular Hemostatic Disease

Drugs for Vascular Hemostatic Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 780)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bortezomib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 179324-69-7 387447 93860
2
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
3
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-02-2 5743
4
Epirubicin Approved Phase 4,Phase 3,Phase 2 56420-45-2 41867
5
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
6
Zoledronic acid Approved Phase 4,Phase 3,Phase 2,Phase 1 118072-93-8 68740
7
Warfarin Approved Phase 4,Phase 3,Phase 1 81-81-2 54678486 6691
8
Tranexamic Acid Approved Phase 4,Phase 2,Phase 3 1197-18-8 5526
9
Melphalan Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 148-82-3 460612 4053
10
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 53-03-2 5865
11
Lenalidomide Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 191732-72-6 216326
12
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 135968-09-1
13
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 104987-11-3 445643 439492
14
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
15
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
16
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
17
Dalteparin Approved Phase 4,Phase 3,Phase 2,Phase 1 9005-49-6
18
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 9005-49-6 46507594 772
19
Thrombin Approved, Investigational Phase 4,Phase 3,Phase 2
20
Cytarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 147-94-4 6253
21
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 33419-42-0 36462
22
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 174722-31-7 10201696
23
Bevacizumab Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 216974-75-3
24
Apixaban Approved Phase 4,Phase 3,Phase 2 503612-47-3 10182969
25
Iron Approved Phase 4,Phase 3,Phase 2,Phase 1 7439-89-6 23925
26
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
27
Acenocoumarol Approved, Investigational Phase 4 152-72-7 54676537 9052
28 fluindione Approved, Investigational Phase 4 957-56-2
29
Phenindione Approved, Investigational Phase 4 83-12-5 4760
30
Mesna Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 3375-50-6 598
31
Celiprolol Approved, Investigational Phase 4 56980-93-9
32
Phentolamine Approved Phase 4 50-60-2 5775
33 Thiotepa Approved, Investigational Phase 4,Phase 2,Phase 1 52-24-4 5453
34 Ixazomib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 1072833-77-2
35
Menthol Approved Phase 4,Phase 1 2216-51-5 16666
36
Menadione Approved, Nutraceutical Phase 4,Phase 3 58-27-5 4055
37
Phytonadione Approved, Investigational, Nutraceutical Phase 4,Phase 3 84-80-0 5284607 4812
38
Glycine Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 56-40-6 750
39
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1 31703
40
Pirarubicin Investigational Phase 4 72496-41-4
41 Anesthetics Phase 4,Phase 3,Phase 2,Phase 1
42 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1
43 Blood Substitutes Phase 4,Phase 3,Phase 2
44 Hydroxyethyl Starch Derivatives Phase 4,Phase 2
45 Plasma Substitutes Phase 4,Phase 3,Phase 2
46 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
47 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
48 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
49 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
50 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 2724)

# Name Status NCT ID Phase Drugs
1 The Effect of Human Albumin on Coagulation Competence and Hemorrhage Unknown status NCT02270723 Phase 4 5% Human Albumin " Behring";Lactated Ringer
2 Study Using Plasma for Patients Requiring Emergency Surgery Unknown status NCT01221389 Phase 4 Human Plasma
3 Trial of HoLEP vs. PVP in Treating BPH in Patients With Bleeding Tendency Unknown status NCT02293759 Phase 4
4 A Study of PAD Versus Velcade, Cyclophosphamide and Dexamethasone (VCD) Treatment in Subjects With Multiple Myeloma Unknown status NCT01868828 Phase 4 PAD;VCD
5 Pseudohyponatremia of Multiple Myeloma is True Hyponatremia Unknown status NCT01425606 Phase 4
6 Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma Unknown status NCT01249690 Phase 4 Bortezomib,Pirarubicin,Dexamethasone;Thalidomide,Pirarubicin,Dexamethasone
7 Stage I Multiple Myeloma Treatment Unknown status NCT00733538 Phase 4 zometa
8 Free Fatty Acid-Induced Hypertension in Obese Subjects With Type 2 Diabetes Completed NCT00738023 Phase 4 Rosiglitazone;Normal saline 0.9%;Intralipid 20%
9 Effect of Colloid Versus Crystalloid on Coagulation in Elective Urological Surgery Completed NCT02009033 Phase 4 Lactated Ringer;Hydroxyethylstarch
10 Hemodilution and Coagulopathy With 3 Colloids Completed NCT01727830 Phase 4
11 The Effect of the Hemobag® Ultrafiltration System on Blood Conservation and Coagulation After Cardiopulmonary Bypass Completed NCT01435304 Phase 4
12 Anticoagulant Clinics and Vitamin K Antagonists Completed NCT00966290 Phase 4 Anticoagulant (warfarin, acenocoumarol, fluindione);Anticoagulant (warfarin, acenocoumarol, fluindione)
13 Goal-orientated Therapy of Perioperative Disturbance in Hemostasis in Cardiac Surgery Completed NCT00516126 Phase 4
14 Fibrinogen for Treatment of Pediatric Dilutional Coagulopathy. FibPaed Study. Completed NCT01487837 Phase 4 Human fibrinogen concentrate
15 The Assessment of Tranexamic Acid in Women With Menorrhagia Who Have Bleeding Disorders Completed NCT00904709 Phase 4 tranexamic acid
16 Comparison of Three Management Strategies for Post Cardiac Surgery Bleeding Completed NCT00188747 Phase 4
17 Fibrinogen as an Alternative to FFP in Aortic Surgery. Completed NCT00994045 Phase 4
18 Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery Completed NCT01561391 Phase 4 activated recombinant human factor VII;activated recombinant human factor VII;factor VIII
19 High Dose of Activated Recombinant Human Factor VII for Treatment of Mild/Moderate Joint Bleeds in Haemophilia Patients With Inhibitors Completed NCT00571584 Phase 4 activated recombinant human factor VII
20 Trial of NovoSeven® in Haemophilia - Joint Bleeds Completed NCT00108797 Phase 4 eptacog alfa (activated);Feiba VH
21 Study of Safety and Efficacy of Antihemophilic Factor/Von Willebrand Factor Complex in Surgical Subjects With Von Willebrand Disease (vWD) Completed NCT00168090 Phase 4 Blood coagulation Factor VIII and vWF, human
22 Observational Study to Evaluate the Efficacy and Safety of Bortezomib, Melphalan, Prednisone (VMP) in Participants With Multiple Myeloma Completed NCT02474563 Phase 4 Bortezomib;Melphalan;Prednisone
23 A Pharmacokinetic Study of Bortezomib in Taiwanese Participants With Multiple Myeloma Completed NCT02268890 Phase 4 Bortezomib
24 Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma Completed NCT01731886 Phase 4 Lenalidomide;Dexamethasone
25 An Observational Study of Chinese Multiple Myeloma Patients Treated With Velcade Completed NCT01675245 Phase 4 No intervention
26 Retrospective Survey of Re-treatment With Bortezomib Completed NCT01524445 Phase 4
27 A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure Completed NCT01241396 Phase 4
28 Quality of Life of Non-transplant Candidate Multiple Myeloma Patients Treated With Early Bortezomib Completed NCT01060202 Phase 4 No intervention
29 A Retreatment Study With Bortezomib for Multiple Myeloma Completed NCT01030302 Phase 4 bortezomib
30 Observational Study of the Effects Intravenous Bortezomib Has on Osteoblast (Cell That is Responsible for Bone Formation) Activity in Multiple Myeloma Patients. Completed NCT01026701 Phase 4 bortezomib
31 Quality of Life in Multiple Myeloma Patients Treated With Bortezomib Completed NCT01021592 Phase 4 bortezomib
32 Tacrolimus in Children With Henoch-Schönlein Purpura Nephritis Completed NCT03222687 Phase 4 tacrolimus;prednisone
33 Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma Completed NCT00652041 Phase 4 Bortezomib;Thalidomide;Bortezomib
34 Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Patients Completed NCT00622505 Phase 4 zoledronic acid
35 VALEO: A Post Authorization Study, Designed to Learn More About the Safety and Effectiveness of the Use of Bortezomib in the Netherlands Completed NCT00440765 Phase 4 bortezomib
36 ADVANCE: An Observational Study To Determine Bortezomib Safety and Effectiveness at First Relapse After Participation In First Line HOVON-49/50 Clinical Studies. Completed NCT00440479 Phase 4 Bortezomib
37 Observational Study in Participants With Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM) and Non-Hodgkin's Lymphoma (NHL) in Latin America Completed NCT02559583 Phase 4
38 Bortezomib (Velcade) - Regulatory Post Marketing Surveillance (PMS) Completed NCT01005628 Phase 4 bortezomib
39 Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability Completed NCT00257114 Phase 4 bortezomib
40 Investigation of Coagulation Parameters in Hereditary Haemorrhagic Telangiectasia Completed NCT00230659 Phase 4
41 FREE Study - Fracture Reduction Evaluation Completed NCT00211211 Phase 4
42 Celiprolol in Patients With Ehlers-Danlos Syndrome, Vascular Type Completed NCT00190411 Phase 4 celiprolol;Control
43 A Multiple Myeloma Trial in Patients With Bone Metastases Completed NCT00104104 Phase 4 zoledronic acid
44 Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone Metastases Completed NCT00434447 Phase 4 Zoledronic acid
45 HSP-glomerulonephritis Trial: MP vs CyA Completed NCT00425724 Phase 4 Methylprednisolone pulses plus prednisone versus Cyclosporine A
46 PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation Completed NCT00352703 Phase 4 Kepivance (Palifermin)
47 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
48 Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions Completed NCT00029224 Phase 4 zoledronic acid
49 Residual Anti-Xa Activity After Last Treatment Dose of Enoxaparin Recruiting NCT03296033 Phase 4 Enoxaparin;Enoxaparin
50 Pilot Study to Compare Fresh Frozen Plasma With 24-Hour Plasma in Babies Up to Age Six Months Recruiting NCT02774317 Phase 4

Search NIH Clinical Center for Vascular Hemostatic Disease

Cochrane evidence based reviews: hemostatic disorders

Genetic Tests for Vascular Hemostatic Disease

Anatomical Context for Vascular Hemostatic Disease

MalaCards organs/tissues related to Vascular Hemostatic Disease:

38
Bone, Bone Marrow, T Cells, B Cells, Testes, Kidney, Liver

Publications for Vascular Hemostatic Disease

Articles related to Vascular Hemostatic Disease:

(show all 13)
# Title Authors Year
1
Hemostatic Disorders in Hormonally Active Pituitary Tumors. ( 26285071 )
2015
2
Hemostatic disorders in a JAK2V617F-driven mouse model of myeloproliferative neoplasm. ( 24951423 )
2014
3
[Association of hemostatic disorders in diabetic patients with methylenetetrahydrofolate reductase (C677T) and coagulation factors II (G20210A) and V (G1691A) gene polymorphism]. ( 21574459 )
2011
4
Thrombocytopenia and hemostatic disorders in chronic graft versus host disease. ( 19684626 )
2009
5
A link between a hemostatic disorder and preterm PROM: a role for tissue factor and tissue factor pathway inhibitor. ( 19012190 )
2008
6
Use of the levonorgestrel-releasing intrauterine system in women with hemostatic disorders. ( 18001734 )
2008
7
Homocysteine and hemostatic disorder as a risk factor for myocardial infarction at a young age. ( 12818247 )
2003
8
[An inherited hemostatic disorder as the cause of menorrhagia]. ( 11938574 )
2002
9
[Recurrent epistaxis in children as an indicator of hemostatic disorders]. ( 9949588 )
1998
10
[Hemostatic disorders as a complication of autoimmune hemolytic anemia in dogs]. ( 9499627 )
1998
11
Hemostatic disorders associated with arterial hypertension and peripheral arterial disease. ( 8522567 )
1995
12
[The Willebrand factor in the diagnosis of hemostatic disorders in patients with rheumatoid arthritis]. ( 1710721 )
1991
13
[Characteristics of hemostatic disorders in septic shock in children]. ( 2396772 )
1990

Variations for Vascular Hemostatic Disease

Expression for Vascular Hemostatic Disease

Search GEO for disease gene expression data for Vascular Hemostatic Disease.

Pathways for Vascular Hemostatic Disease

GO Terms for Vascular Hemostatic Disease

Biological processes related to Vascular Hemostatic Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to hydrogen peroxide GO:0042542 8.96 HBA1 PDCD10
2 positive regulation of protein localization to nucleus GO:1900182 8.62 CD2AP F2

Sources for Vascular Hemostatic Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....